Differential effects of cyclosporin A on the alloreactivity of fresh and ex vivo-expanded T lymphocytes

Bone Marrow Transplantation

Volumn 22, Issue 11, 1998, Pages 1097-1102

  Contassot, E ^a,e   Robinet, E ^a   Angonin, R ^b   Laithier, V ^a   Bittencourt, M ^a   Pavy, J J ^c   Cahn, J Y ^d   Herve P ^a   Tiberghien, P ^a  

^a Etablissement de Transfus Sanguine   (France)

^b UFR des Sciences Med et Pharmaceut   (France)

^c Service de radiothérapie   (France)

^d UNIVERSITY HOSPITAL OF BESANÇON   (France)

^e Immuno Molec Therapeut Laboratory   (France)

Author keywords

Alloreactivity; Bone marrow transplantation; Cellular therapy; Cyclosporin A; Graft versus host disease

Indexed keywords

CYCLOSPORIN A; INTERLEUKIN 2;

ALLOIMMUNITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW TRANSPLANTATION; CELLULAR IMMUNITY; CONTROLLED STUDY; GENETIC ENGINEERING; GRAFT VERSUS HOST REACTION; LYMPHOCYTE PROLIFERATION; MALE; MORTALITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL; T LYMPHOCYTE;

EID: 0031758236     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1701492     Document Type: Article

References (28)

1. Marmont AM, Horowitz MM, Gale RP et al. T cell depletion of HLA-identical transplant in leukemia. Blood 1991; 78: 2120-2130.
2. Tiberghien P. Use of suicide genes in gene therapy. J Leukocyte Biol 1994; 56: 203-209.
3. Kit S, Leung, WC, Jorgensen GN, Dubbs DR. Distinctive properties of thymidine kinase isozymes induced by human and avian herpes virus. Int J Cancer 1974; 14: 598-610.
4. Tiberghien P, Reynolds CW, Spence S et al. Ganciclovir treatment of herpes simplex thymidine kinase-transduced primary T-lymphoeytes: an approach for specific in vivo donor T cell depletion after allogeneic bone marrow transplantation? Blood 1994; 84: 1333-1341.
5. Tiberghien P, Cahn JY, Brion A et al. Use of donor T-lymphocytes expressing herpes-simplex thymidine kinase in allogeneic bone marrow transplantation - a phase I study. Hum Gene Ther 1997; 8: 615-624.
6. Powles RL, Clink HM, Spence D et al. Cyclosporin A to prevent graft-versus-host disease in man after allogeneic bone marrow transplantation. Lancet 1980; 8164: 327-329.
7. Deeg HJ, Storb R, Thomas ED et al. Cyclosporin as a prophylaxis for graft-versus-host disease: a randomized study in patients undergoing marrow transplantation for acute nonlymphoblastic leukemia. Blood 1985; 65: 1325-1334.
8. Bunjes D, Hardt C, Röllinghoff C, Wagner H. Cyclosporin A mediates immunosuppression of primary cytotoxic T cell responses by impairing the release of interleukin-1 and interleukin-2. Eur J Immunol 1981; 11: 657-661.
9. Contassot E, Murphy W, Angonin R et al In vivo alloreactive potential of ex vivo-expanded primary T-lymphocytes. Transplantation 1998; 65: 1365-1370.
10. Contassot E, Ferrand C, Certoux JM et al. Retrovirus-mediated transfer of the herpes simplex type I thymidine kinase gene in alloreactive T lymphocytes. Hum Gene Ther 1998; 1: 73-80.
11. Hess AD. Effect of interleukin-2 on the immunosuppressive action of cyclosporin. Transplantation 1985; 39: 62-68.
12. Herold KC, Lancki DW, Moldwin RL, Fitch FW. Immunosuppressive effects of cyclosporin A on cloned T cells. J Immunol 1986; 136: 1315-1321.
13. Heeg K, Deusch K, Solbach W et al. Frequency analysis of cyclosporin-sensitive cytotoxic T lymphocyte precursors. Transplantation 1984; 38: 532-536.
14. Handschumacher RE, Harding MW, Rice J et al. Cyclophilin: a specific cytosolic binding protein for cyclosporm A. Science 1984; 226: 544-547.
15. Balakrishnan K, Pandey A. The panorama of cyclosporin research. J Basic Microbiol 1996; 36: 121-147.
16. Liu J, Farmer JD, Lane WS et al. Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes. Cell 1991; 66: 807-815.
17. Flanagan WM, Corthesy B, Bram RJ, Crabtree GR. Nuclear association of a T-cell transcription factor blocked by FK-506 and cyclosporin A. Nature 1991; 352: 803-807.
18. Krönke M, Leonard WJ, Depper JM et al. Cyclosporin A inhibits T cell growth factor gene expression at the level of mRNA transcription. Proc Natl Acad Sci USA 1984; 81: 5214-5218.
19. Storb R, Deeg HJ. Fisher L et al. Cyclosporin vs methotrexate for graft-versus-host disease prevention in patients given marrow grafts for leukemia: long-term follow-up of three controlled trials. Blood 1988; 71: 293-298.
20. Kennedy MS, Deeg HJ, Storb R et al Treatment of acute graft-versus-host disease after allogeneic marrow transplantation. Randomized study comparing corticosteroids and cyclosporine. Am J Med 1985; 78: 978-983.
21. Ferrara JLM, Cooke KR, Pan L, Krenger W. The immunopathophysiology of acute graft-versus-host disease. Stem Cells 1996; 14: 473-489.
22. Allen RD, Staley TA, Sidman CL. Differential cytokine expression in acute and chronic murine graft-versus-host disease. Eur J Immunol 1993; 23: 333-337.
23. Smith SR, Terminelli C, Kenworthy-Bott L, Phillips DL. A study of cytokine production in acute graft-vs-host disease. Cell Immunol 1991; 134: 336-348.
24. Mowat AM. Antibidies to IFN-gamma prevent immunologically mediated intestinal damage in murine graft-versus-host reaction. Immunology 1989; 68: 18-23.
25. Brok HPM, Heidt PJ, Van der Meide PH et al. Interferon-γ prevents graft-versus-host disease after allogeneic bone marrow transplantation in mice. J Immunol 1993; 151: 6451- 6459.
26. Kumpel GR, Annable CR, Cleveland MG et al. Immunosuppression and lymphoid hypoplasia associated with chonic graft-versus-host disease is dependent upon IFN-gamma production. J Immunol 1990; 144: 84-93.
27. Bonini C, Ferrari G, Verzeletti S et al. HSV-tk gene transfer into donor lymphocytes for control of allogeneic graft-versus- leukemia. Science 1997; 276: 1719-1724.
28. Rooney CM, Smith CA, Ng CY et al. Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr virus- related lymphoproliferation. Lancet 1995; 345: 9-13.